Vericel Corp
VCEL
Company Profile
Business description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Contact
64 Sidney Street
CambridgeMA02139
USAT: +1 617 588-5555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
357
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
With a focus on leveraging its AI investments, here’s what we think of Meta stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 15.30 | 0.17% |
| CAC 40 | 7,757.12 | 41.10 | -0.53% |
| DAX 40 | 24,101.78 | 206.02 | -0.85% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,017.77 | 4.78 | 0.05% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
| NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |